Samsung Biologics company profile
Company profile
Samsung Biologics has 5,326 employees and is headquartered in Incheon, South Korea.
The business centres on manufacturing biopharmaceutical products, which it also commercializes, distributes and sells. Its development work runs from cell line development and process development to analytical development and non-GMP and CGMP manufacturing. Downstream, it operates aseptic filling, freeze-drying, packaging and cold-chain logistics, alongside quality services such as stability studies, environmental monitoring and biosafety testing. Its portfolio also includes antibody-drug conjugates and mRNA products, and its customers and sales reach South Korea, Europe, the United States and other international markets.
In the fiscal year ended December 2025, revenue totalled 4,557.0 billion won, up 30.3% from the prior year, while net income reached 1,784.4 billion won. The company employed 5,326 people and has its headquarters in Incheon, South Korea, where it was set up in 2011.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- South Korea
- Headquarters
- 300, Songdo bio-daero, Incheon
- Employees
- 5,326
- Chief executive
- John Chongbo Rim
- Founded
- 2011
- Fiscal year
- January - December
- Listing
- 207940 · KRX
- Currency
- KRW
- ISIN
- KR7207940008
- Website
- samsungbiologics.com
Samsung Biologics and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Samsung Biologics207940 | South Korea | $49.26B | 5,326 | 45.5% | 31.2 |
| CSLCSL | Australia | $64.31B | 29,000 | 26.8% | — |
| Celltrion068270 | South Korea | $36.53B | 2,956 | 31.6% | 31.4 |
| WuXi Biologics (Cayman)2269 | Hong Kong SAR China | $24.29B | 14,705 | 32.4% | 35.1 |
| Innovent Biologics1801 | Hong Kong SAR China | $18.84B | 8,754 | 7.4% | 111.5 |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | Hong Kong SAR China | $13.65B | 2,300 | -0.2% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
